Sirkhazi Mansoor, Sarriff Azmi, Aziz Noorizan Abd, Almana Fatma, Arafat Osama, Shorman Mahmoud
Department of Pharmacy, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
School of Pharmaceutical Sciences, University Sains Malaysia, 11800 Minden, Penang, Malaysia.
World J Oncol. 2014 Dec;5(5-6):196-203. doi: 10.14740/wjon850w. Epub 2014 Dec 3.
Knowing local spectrum and sensitivity for bacterial isolates causing febrile neutropenia is important as starting an appropriate empirical antibiotic therapy is considered a medical emergency in these high-risk patients.
A retrospective study of a total of 106 microbiologically febrile episodes in hospitalized adult neutropenic cancer patients, who were admitted from May 2009 to May 2013, at King Fahad Specialist Hospital, Dammam, Saudi Arabia, was conducted.
Among 106 microbiologically documented febrile neutropenic episodes, the majority of malignancies were solid tumors accounting for 53.8% (57/106) and hematological malignancies accounted for 46.23% (49/106). The most common malignancies were non-Hodgkin's lymphoma 19.81% (21/106) followed by acute myeloid leukemia 15.09% (16/106), then colorectal cancer 13.21% (14/106), pancreatic cancer and acute lymphoblastic leukemia accounting for 5.66% (6/106) each, multiple myeloma 4.72% (5/106), gall bladder cancer 3.77% (4/106), and lung cancer 2.83% (3/106). A total of 138 bacterial isolates were identified. The overall prevalence of gram-negative bacteria was 65.94% (91/138) and for gram-positive bacteria was 34.06% (47/138). The most common bacterial isolation sites were blood 33.32% (46 isolates), urine 29.71% (41 isolates), wound 19.55% (27 isolates), body fluids 9.41% (13 isolates) and sputum 7.96% (11 isolates). The most predominant pathogens were 30.43 (42/138), 14.49% (20/138), 13.04% (18/138), spp. 7.25% (10/138), spp. 7.25% (10/138), spp. 5.80% (8/138), spp. 4.35% (6/138), spp. 3.62% (5/138), spp. 3.62% (5/138), spp. 2.90% (4/138), 2.17% (3/138), 1.45% (2). and contributed to 0.72% with one isolate each. For gram-negative and , the extended-spectrum beta-lactamases producers (ESBLs) rates were 38% and 22.22% respectively. For Pseudomonas aerugenosa imipenem-cilastatin resistance rate was 18.84%. For gram-positive bacteria, methicillin-resistant (MRSA) rate was 28.62%. The vancomycin-resistant (VRE) rate was 1.18%.
Gram-negative bacteria were more prevalent as a cause of infection in adult cancer patients with febrile neutropenia at our institution, with and with high ESBLs rates being the most common pathogens. Blood stream infections followed by urinary tract infections were the most common sites of infection. The use of initial antibiotic therapy in febrile neutropenic episodes should be based on local bacterial spectrum and susceptibility/sensitivity patterns to prevent treatment failure with increased morbidity and mortality.
了解引起发热性中性粒细胞减少症的细菌分离株的本地谱和敏感性很重要,因为对这些高危患者开始适当的经验性抗生素治疗被视为医疗紧急情况。
对2009年5月至2013年5月在沙特阿拉伯达曼法赫德国王专科医院住院的成年中性粒细胞减少癌症患者的总共106次微生物学发热发作进行了回顾性研究。
在106次微生物学记录的发热性中性粒细胞减少发作中,大多数恶性肿瘤为实体瘤,占53.8%(57/106),血液系统恶性肿瘤占46.23%(49/106)。最常见的恶性肿瘤是非霍奇金淋巴瘤19.81%(21/106),其次是急性髓系白血病15.09%(16/106),然后是结直肠癌13.21%(14/106),胰腺癌和急性淋巴细胞白血病各占5.66%(6/106),多发性骨髓瘤4.72%(5/106),胆囊癌3.77%(4/106),肺癌2.83%(3/106)。共鉴定出138株细菌分离株。革兰氏阴性菌的总体患病率为65.94%(91/138),革兰氏阳性菌为34.06%(47/138)。最常见的细菌分离部位是血液33.32%(46株),尿液29.71%(41株),伤口19.55%(27株),体液9.41%(13株)和痰液7.96%(11株)。最主要的病原体是 30.43(42/138),14.49%(20/138),13.04%(18/138),spp. 7.25%(10/138),spp. 7.25%(10/138),spp. 5.80%(8/138),spp. 4.35%(6/138),spp. 3.62%(5/138),spp. 3.62%(5/138),spp. 2.90%(4/138),2.17%(3/138),1.45%(2)。 和 各有1株分离株,占0.72%。对于革兰氏阴性 和 ,超广谱β-内酰胺酶产生菌(ESBLs)率分别为38%和22.22%。对于铜绿假单胞菌,亚胺培南-西司他丁耐药率为18.84%。对于革兰氏阳性菌,耐甲氧西林 (MRSA) 率为28.62%。耐万古霉素 (VRE) 率为1.18%。
在我们机构中,革兰氏阴性菌作为发热性中性粒细胞减少的成年癌症患者感染原因更为普遍, 和 且ESBLs率高是最常见的病原体。血流感染其次是尿路感染是最常见的感染部位。发热性中性粒细胞减少发作的初始抗生素治疗应基于当地细菌谱和药敏/敏感性模式,以防止治疗失败并增加发病率和死亡率。